Bristol Vanlev Trial In Refractory Patients Could Support Approval, Cmte. Says
Executive Summary
Results from a trial of Bristol-Myers Squibb's Vanlev in highly refractory hypertension patients showing a benefit over current therapy could outweigh safety concerns with the drug and lead to approval, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded at its July 19 meeting